북미의 오가노이드 서비스 시장(2021-2031년) : 범위, 세분화, 동향, 경쟁 분석

The North America organoid services market is projected to grow significantly, reaching approximately US$ 6,574.44 million by 2031, up from US$ 1,640.88 million in 2024, reflecting a robust compound annual growth rate (CAGR) of 21.9% during this period.

Executive Summary and Market Analysis

The market is divided into three primary regions: the United States, Canada, and Mexico, with the US anticipated to dominate the market share in 2024. Key drivers of growth in the organoid services market include the rising prevalence of chronic diseases and viral infections, the commercialization of organoid models, increased research and development activities, and advancements in stem cell research.

Market Segmentation Analysis

The North America organoid services market can be segmented based on type, application, and source:

• By Type: The market includes various organoid types such as intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment is expected to hold the largest market share in 2024.
• By Application: Applications are categorized into developmental biology disease, infectious disease pathology, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, among others. The developmental biology disease segment is projected to lead the market in 2024.
• By Source: The market is divided into pluripotent stem cells and organ-specific adult stem cells, with pluripotent stem cells expected to dominate in 2024.

Market Outlook

Organoids are becoming essential tools for researchers and pharmaceutical developers, offering more efficient and precise methods for identifying promising drug candidates and predicting their effectiveness. The ability to create patient-derived organoids presents exciting opportunities for personalized drug screening. Unlike traditional 2D cell cultures, organoids replicate the complexity of human organs, including their cellular makeup, structure, and function, which leads to more accurate drug response predictions. This capability allows researchers to identify potential drug candidates with greater confidence, reducing the risk of costly failures in clinical trials.

The organoid services market is experiencing rapid expansion due to the increasing demand for innovative screening services. By utilizing organoids derived from patients' cells, researchers can customize drug testing to individual responses, enhancing the chances of successful treatments through personalized approaches. The integration of advanced technologies, such as high-throughput screening and automated image analysis, further boosts the effectiveness of organoid screening services. This combination allows researchers to efficiently test numerous drug compounds, analyze results with greater accuracy, and expedite the drug discovery process. The global emphasis on innovative screening services, driven by the rise of personalized medicine and the need for faster drug development, supports the growth of the North America organoid services market.

In January 2024, HUB Organoids launched the IntegriGut Screen, a novel screening service that utilizes patient-derived organoid monolayers from inflammatory bowel disease (IBD) patients. This service provides high-quality human data on epithelial barrier function, facilitating the development of new therapies for IBD.

Country Insights

The North America organoid services market is primarily composed of the US, Canada, and Mexico, with the US holding the largest market share in 2024. Companies in the US organoid services market are focusing on organic growth strategies to enhance their market presence. For instance, in February 2023, Molecular Devices, LLC and HUB Organoids announced a strategic partnership aimed at advancing next-generation 3D biology technologies to significantly reduce drug attrition rates from preclinical to clinical stages.

The increasing research and development activities, along with a growing demand for tissue engineering and organ transplantation, are propelling the organoid services market in the US. Organoids have the potential to address several limitations previously faced in biomedical research, such as gaining insights into human development, creating accurate disease models, and generating patient-matched tissues for regenerative medicine. Research funding and venture capital investments have also played a crucial role in advancing human organoid development. For example, a collaborative project funded by the National Science Foundation, valued at approximately US$ 1.5 million, aims to enhance brain organoid development processes and improve the consistency and reliability of end products for researchers.

Company Profiles

Key players in the North America organoid services market include CUSABIO TECHNOLOGY LLC, Cyprio, Eurofins Scientific SE, HUB Organoids B.V., InnoSer, InSphero, LABTOO, Molecular Devices, LLC, Oncodesign Services, and Sino Biological Inc. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their offerings and increase market share.

Table Of Contents

1. Introduction

• 1.1 Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Secondary Research
• 3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. North America Organoids Services Market Landscape

• 4.1 PEST Analysis

5. North America Organoids Services Market - Key Market Dynamics

• 5.1 North America Organoids Services Market - Key Market Dynamics
• 5.2 Market Drivers
  • 5.2.1 Increasing Demand for Innovative Drug Screening Services
  • 5.2.2 Surge in Popularity of Personalized Drugs
• 5.3 Market Restraints
  • 5.3.1 Dearth of Skilled Professionals
• 5.4 Market Opportunities
  • 5.4.1 Increasing Key Developments
• 5.5 Future Trends
  • 5.5.1 Integration of Artificial Intelligence
• 5.6 Impact of Drivers and Restraints:

6. North America Organoids Services Market - Analysis

• 6.1 North America Organoids Services Market Revenue (US$ Million), 2021-2031
• 6.2 North America Organoids Services Market Forecast Analysis

7. North America Organoids Services Market Analysis - by Type

• 7.1 Intestine
  • 7.1.1 Overview
  • 7.1.2 Intestine: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.2 Liver
  • 7.2.1 Overview
  • 7.2.2 Liver: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.3 Stomach
  • 7.3.1 Overview
  • 7.3.2 Stomach: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.4 Pancreas
  • 7.4.1 Overview
  • 7.4.2 Pancreas: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.5 Lung
  • 7.5.1 Overview
  • 7.5.2 Lung: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.6 Brain
  • 7.6.1 Overview
  • 7.6.2 Brain: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.7 Kidney
  • 7.7.1 Overview
  • 7.7.2 Kidney: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.8 Others
  • 7.8.1 Overview
  • 7.8.2 Others: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. North America Organoids Services Market Analysis - by Application

• 8.1 Developmental Biology Disease
  • 8.1.1 Overview
  • 8.1.2 Developmental Biology Disease: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 8.2 Pathology of Infectious Disease
  • 8.2.1 Overview
  • 8.2.2 Pathology of Infectious Disease: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 8.3 Regenerative Medicine
  • 8.3.1 Overview
  • 8.3.2 Regenerative Medicine: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 8.4 Drug Toxicity and Efficacy Testing
  • 8.4.1 Overview
  • 8.4.2 Drug Toxicity and Efficacy Testing: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 8.5 Drug Discovery and Personalized Medicine
  • 8.5.1 Overview
  • 8.5.2 Drug Discovery and Personalized Medicine: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 8.6 Others
  • 8.6.1 Overview
  • 8.6.2 Others: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. North America Organoids Services Market Analysis - by Source

• 9.1 Pluripotent Stem Cells
  • 9.1.1 Overview
  • 9.1.2 Pluripotent Stem Cells: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 9.2 Organ Specific Adult Stem Cell
  • 9.2.1 Overview
  • 9.2.2 Organ Specific Adult Stem Cell: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. North America Organoids Services Market - Country Analysis

• 10.1 North America
  • 10.1.1 North America Organoids Services Market - Revenue and Forecast Analysis - by Country
    • 10.1.1.1 North America Organoids Services Market - Revenue and Forecast Analysis - by Country
    • 10.1.1.2 United States: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.1.1.2.1 United States: North America Organoids Services Market Share - by Type
      • 10.1.1.2.2 United States: North America Organoids Services Market Share - by Application
      • 10.1.1.2.3 United States: North America Organoids Services Market Share - by Source
    • 10.1.1.3 Canada: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.1.1.3.1 Canada: North America Organoids Services Market Share - by Type
      • 10.1.1.3.2 Canada: North America Organoids Services Market Share - by Application
      • 10.1.1.3.3 Canada: North America Organoids Services Market Share - by Source
    • 10.1.1.4 Mexico: North America Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.1.1.4.1 Mexico: North America Organoids Services Market Share - by Type
      • 10.1.1.4.2 Mexico: North America Organoids Services Market Share - by Application
      • 10.1.1.4.3 Mexico: North America Organoids Services Market Share - by Source

11. Industry Landscape

• 11.1 Overview
• 11.2 Growth Strategies in Organoids Services Market
• 11.3 Organic Growth Strategies
  • 11.3.1 Overview
• 11.4 Inorganic Growth Strategies
  • 11.4.1 Overview

12. Company Profiles

• 12.1 Sino Biological Inc.
  • 12.1.1 Key Facts
  • 12.1.2 Business Description
  • 12.1.3 Products and Services
  • 12.1.4 Financial Overview
  • 12.1.5 SWOT Analysis
  • 12.1.6 Key Developments
• 12.2 Eurofins Scientific SE
  • 12.2.1 Key Facts
  • 12.2.2 Business Description
  • 12.2.3 Products and Services
  • 12.2.4 Financial Overview
  • 12.2.5 SWOT Analysis
  • 12.2.6 Key Developments
• 12.3 Molecular Devices, LLC.
  • 12.3.1 Key Facts
  • 12.3.2 Business Description
  • 12.3.3 Products and Services
  • 12.3.4 Financial Overview
  • 12.3.5 SWOT Analysis
  • 12.3.6 Key Developments
• 12.4 InSphero
  • 12.4.1 Key Facts
  • 12.4.2 Business Description
  • 12.4.3 Products and Services
  • 12.4.4 Financial Overview
  • 12.4.5 SWOT Analysis
  • 12.4.6 Key Developments
• 12.5 Cyprio
  • 12.5.1 Key Facts
  • 12.5.2 Business Description
  • 12.5.3 Products and Services
  • 12.5.4 Financial Overview
  • 12.5.5 SWOT Analysis
  • 12.5.6 Key Developments
• 12.6 InnoSer
  • 12.6.1 Key Facts
  • 12.6.2 Business Description
  • 12.6.3 Products and Services
  • 12.6.4 Financial Overview
  • 12.6.5 SWOT Analysis
  • 12.6.6 Key Developments
• 12.7 LABTOO
  • 12.7.1 Key Facts
  • 12.7.2 Business Description
  • 12.7.3 Products and Services
  • 12.7.4 Financial Overview
  • 12.7.5 SWOT Analysis
  • 12.7.6 Key Developments
• 12.8 CUSABIO TECHNOLOGY LLC
  • 12.8.1 Key Facts
  • 12.8.2 Business Description
  • 12.8.3 Products and Services
  • 12.8.4 Financial Overview
  • 12.8.5 SWOT Analysis
  • 12.8.6 Key Developments
• 12.9 Oncodesign Services
  • 12.9.1 Key Facts
  • 12.9.2 Business Description
  • 12.9.3 Products and Services
  • 12.9.4 Financial Overview
  • 12.9.5 SWOT Analysis
  • 12.9.6 Key Developments
• 12.10 HUB Organoids B.V. (Hubrecht Organoid Technology)
  • 12.10.1 Key Facts
  • 12.10.2 Business Description
  • 12.10.3 Products and Services
  • 12.10.4 Financial Overview
  • 12.10.5 SWOT Analysis
  • 12.10.6 Key Developments

13. Appendix

• 13.1 About The Insight Partners
• 13.2 Glossary of Terms